Peroxiredoxin-4, a Marker of Systemic Oxidative Stress, is Associated with Incident Heart Failure
Circulating Prx4 associates with the risk of developing HF, both with preserved and reduced ejection fraction. Future studies should examine whether Prx4 can serve as a real-time marker of oxidative stress status.
Authors
- Etto C. Eringa (ORCID: https://orcid.org/0000-0002-9814-5149)
- Nils Bömer (ORCID: https://orcid.org/0000-0001-5926-6960)
- Rudolf A. de Boer (ORCID: https://orcid.org/0000-0002-4775-9140)
- Sanne G.J. Mourmans (ORCID: https://orcid.org/0000-0003-3408-6511)
- Jerremy Weerts (ORCID: https://orcid.org/0000-0002-9369-3453)
- Joseph Pierre Aboumsallem (ORCID: https://orcid.org/0000-0001-8186-6620)
- Stephan J. L. Bakker (ORCID: https://orcid.org/0000-0003-3356-6791)
- Ron T. Gansevoort
- Anouk Achten (ORCID: https://orcid.org/0009-0005-0763-7551)
- Navin Suthahar (ORCID: https://orcid.org/0000-0002-7781-2897)
- Isabella Kardys (ORCID: https://orcid.org/0000-0002-2115-9745)
- Kevin Damman (ORCID: https://orcid.org/0000-0003-0190-2228)
- Vanessa P. M. van Empel (ORCID: https://orcid.org/0000-0002-6864-0296)
- Wouter C. Meijers (ORCID: https://orcid.org/0000-0002-3287-6766)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Maastricht University Medical Centre (NL)
- Erasmus MC (NL)
- Maastricht University (NL)
- Amsterdam Neuroscience (NL)
- Erasmus MC Cancer Institute (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1002/ejhf.3653
- Citations
- 2
- Primary Topic
- Redox biology and oxidative stress
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Alnylam Pharmaceuticals
- Hartstichting
- Nierstichting
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Novo Nordisk
- Vifor Pharma
- HORIZON EUROPE Framework Programme
- Daiichi Sankyo Europe